Rapid detection of Mycobacterium tuberculosis complex (MTBC) is a critical step in controlling tuberculosis (TB). In this study, we used IS6110 as the specific identification target to develop a novel hybridization signal amplification method (HSAM) for the rapid and direct detection of MTBC from clinical sputum specimens. This system consists of magnetic bead-linked capture probes for target isolation, dextranbased nanoparticles for amplifying the reporter molecule (biotinylated-FITC), and detection probes (2B-DNA) for binding the nanoparticles. Both the capture and detection probes were specific to the IS6110 target sequence. Our results determined that as few as 10 copies of the IS6110 sequence or 10 M. tuberculosis bacteria could be detected, indicating that the HSAM assay is as sensitive as conventional PCR, and the assay was specific enough to distinguish MTBC from nontuberculosis mycobacteria (NTM). A total of 176 clinical sputum specimens were collected for HSAM evaluation, and the results were compared to those from traditional culture and biochemical identification techniques. This assay had a sensitivity of 88.3%, a specificity of 91.8%, a positive predictive value of 93.8% and a negative predictive value of 84.8% for the detection of MTBC. This technique is highly sensitive and specific, is easy to perform, and does not require any sophisticated detection equipment; thus, this approach has great potential in clinical TB detection and diagnostic applications.
INTRODUCTION
Tuberculosis (TB) is one of the greatest health concerns in developing and industrialized countries, affecting 1.7 billion people worldwide. There are 8 million new cases and around 3 million deaths annually. Alarmingly, the number of TB cases is rising at a rate of 2% per year. Rapid detection of Mycobacterium tuberculosis complex (MTBC) strains is one of the most important factors in minimizing the spread of this disease. In low-and middle-income countries, conventional
The biotinylated capture probe was immobilized on streptavidincoated Dynal magnetic beads, taking advantage of the high affinity between biotin and streptavidin (STV) (12, 23) . The bisbiotinylated detection probe (2B-DNA) was conjugated to DNAstreptavidin nanoparticles (10, 11) . Because each nanoparticle provides multiple binding sites for the biotinylated FITC reporter molecule, a thousand-fold amplification can be achieved (Fig. 1) .
The objective of this study was to determine the sensitivity and specificity of the HSAM assay for MTBC, and to assess its feasibility for the detection of MTBC from clinical specimens. 
HSAM assay
The HSAM assay involved several steps. First, the capture probe was immobilized on the magnetic beads in a 100 µl 
Culture and biochemical methods for diagnosis of MTBC
About half of each pellet containing suspected pulmonary tuberculosis specimens was inoculated into two LowensteinJensen agar slants and incubated at 37 with 5% CO 2 .
Mycobacterial growth was observed over 2-8 weeks after inoculation. Positive cultures for acid-fast bacilli were Rapid identification of M. tuberculosis identified by conventional biochemical tests (8, 16).
Sample preparation for HSAM
To prepare a sample for HSAM evaluation, 500 µl of diluted bacterial culture or sputum pellet was centrifuged at 2800×g for 20 min. The supernatant was removed, and the pellets were resuspended in 500 µl of distilled water. The mixture was vortexed with glass beads and boiled at 100°C for 10 min (6). This process was repeated three times, and then the mixture was centrifuged at 8000×g for 5 min. The resulting supernatant was used in the HSAM assay.
Probe preparation
The detection (2B-DNA) and capture probes were derived from the nucleic acid sequences encoding the insertion sequence IS6110 (GenBank M29899). The capture probe was derived from nucleic acids at positions 431 to 470 with a biotin label on the 5' end. The detection probe was derived from positions 471 to 530 with the 5' and 3' ends labeled with biotin (TaKaRa Biotechnology (Dalian) Co., Ltd, Dalian, China).
IS6110 was selected as a target site that was specifically recognized by the capture and detection probes ( Table 1) . tuberculosis H37Rv. We initially determined the sensitivity of the HSAM assay using a ten-fold serial dilution of the synthetic IS6110 DNA target. The lowest detection limit by the HSAM assay was 10 molecules (Fig. 4a) , which was confirmed by observing the presence of green fluorescent beads. The assay sensitivity was further analyzed using the M. tuberculosis H37Rv strain. The results in Figure 4c indicate that the HSAM assay was able to detect as few as 10 bacteria.
To determine the assay specificity, we tested the following 11 (Fig. 5 a,c) , while the five NTMs and other bacteria were negative (Fig. 5 b,d ). These results confirmed the specificity of the HSAM assay.
A total of 176 clinical sputum specimens collected during the period August 2006 to March 2007 were diagnosed by traditional culture and biochemical identification methods. In parallel, the spent specimen sediments were subjected to DNA extraction and HSAM analysis, the results of which are summarized in Table 2 .
A total of 103 specimens were reported to contain MTBC strains through the standard culture and biochemical methods. The HSAM assay identified 97 specimens with MTBC strains, resulting in 88.3% sensitivity, 91.8% specificity, 93.8% positive predictive value and 84.8% negative predictive value. IS6110 was identified in six specimens that were MTBC culture-negative.
Among the 103 culture-positive MTBC specimens, 12 were IS6110-negative according to the HSAM assay. and acid fast bacilli (AFB) smear method sensitivities vary from 30% to more than 70% (1) . Among the 103 cultures in which MTBC specimens were identified by culture and biochemical techniques, 91 were IS6110-positive in the HSAM assay. In contrast, 12 specimens that were positive by traditional techniques were MTBC-negative in our assay, which may be due to too few bacterial cells in the sputum specimens. However, there were 6 culture-negative, IS6110-positive samples, which could be due to non-specific hybridization during the HSAM assay. The HSAM assay for MTBC detection can be performed anywhere, and there is no need for a contamination-proof hood or specific lab area, as is required for PCR. The HSAM assay can be used to detect different DNA and RNA targets, which is easily accomplished by altering the sequence of the capture and detection probes.
In summary, the present study showed that the HSAM assay can detect MTBC in clinical specimens. The method is highly sensitive and specific, economical, time-saving and simple. Although further adjustments are required to improve its sensitivity and quantitative aspects, we expect that the HSAM assay will be a useful tool for the rapid detection of MTBC.
